(Q24204040)

1

0 references

TianTian Sun

2

0 references

Peizhen Zhang

3

0 references

Jinhui Tian

Cochrane Database of Systematic Reviews

4

0 references

publication date

7 December 2011

0 references

published in

0 references

cites work

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prev

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statin use and the prevention of venous thromboembolism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Use of statins and the subsequent development of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statins and the risk of idiopathic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statins, fibrates, and venous thromboembolism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statins and the risk of idiopathic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Choosing a parenteral anticoagulant agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

The role of dyslipidemia and statins in venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Statins and blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

7 January 2021

Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

1 reference

7 January 2021

Treatment of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

7 January 2021

HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

7 January 2021

ASH evidence-based guidelines: statins in the prevention of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008203.PUB2

7 January 2021